1460934869-e2fd435d-1669-44dd-9608-b42005d0d313

1. A combination containing (a) a compound of formula (I)
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein
-a=a2-a3=a4- represents a bivalent radical of formula
\u2014CH\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(a-1);
\u2014N\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(a-2);
\u2014N\u2550CH\u2014N\u2550CH\u2014\u2003\u2003(a-3);
\u2014N\u2550CH\u2014CH\u2550N\u2014\u2003\u2003(a-4);
\u2014N\u2550N\u2014CH\u2550CH\u2014\u2003\u2003(a-5);
-b1=b2-b3=b4- represents a bivalent radical of formula
\u2014CH\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(b-1);
\u2014N\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(b-2);
\u2014N\u2550CH\u2014N\u2550CH\u2014\u2003\u2003(b-3);
\u2014N\u2550CH\u2014CH\u2550N\u2014\u2003\u2003(b-4);
\u2014N\u2550N\u2014CH\u2550CH\u2014\u2003\u2003(b-5);

n is 0, 1, 2, 3 or 4; and in case -a1=a2-a3=a4- is (a-1), then n may also be 5;
m is 1, 2, 3 and in case -b1=b2-b3=b4- is (b-1), then m may also be 4;
R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl substituted with C1-6alkyloxycarbonyl;
each R2 independently is hydroxy, halo, C1-6alkyl optionally substituted with cyano or \u2014C(\u2550O)R6, C3-7cycloalkyl, C2-6alkenyl optionally substituted with one or more halogen atoms or cyano, C2-6alkynyl optionally substituted with one or more halogen atoms or cyano, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethylthio, \u2014S(\u2550O)pR6, \u2014NH\u2014S(\u2550O)pR6, \u2014C(\u2550O)R6, \u2014NHC(\u2550O)H, \u2014C(\u2550O)NHNH2, \u2014NHC(\u2550O)R6, \u2014C(\u2550NH)R6 or a radical of formula
wherein each A1 independently is N, CH or CR6; and
A2 is NH, O, S or NR6;
X1 is \u2014NR5\u2014, \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014O\u2014, \u2014C(\u2550O)\u2014, C1-4alkanediyl, \u2014CHOH\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014, \u2014X2\u2014C1-4alkanediyl- or \u2014C1-4alkanediyl-X2\u2014;
X2 is \u2014NR5\u2014, \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014O\u2014, \u2014C(\u2550O)\u2014, \u2014CHOH\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014;
R3 is NHR13; NR13R14; \u2014C(\u2550O)\u2014NHR3; \u2014C(\u2550O)\u2014NR13R14; \u2014C(\u2550O)\u2014R15; \u2014CH\u2550N\u2014NH\u2014C(\u2550O)\u2014R16; C1-6alkyl substituted with one or more substituents each independently selected from cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; C1-6alkyl substituted with one or more substituents each independently selected from cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7 and wherein 2 hydrogen atoms bound at the same carbon atom are replaced by C1-4alkanediyl; C1-6alkyl substituted with hydroxy and a second substituent selected from cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; C1-6alkyloxyC1-6alkyl optionally substituted with one or more substituents each independently selected from cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; C2-6alkenyl substituted with one or more substituents each independently selected from halo, cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; C2-6alkynyl substituted with one or more substituents each independently selected from halo, cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; \u2014C(\u2550N\u2014O\u2014R8)\u2014C1-4alkyl; R7 or \u2014X3\u2014R7;
X3 is \u2014NR5\u2014, \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014O\u2014, \u2014C(\u2550O)\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014, \u2014X2\u2014C1-4alkanediyl-, \u2014C1-4alkanediyl-X2a\u2014, \u2014C1-4alkanediyl-X2b\u2014C1-4alkanediyl, \u2014C(\u2550N\u2014OR8)\u2014C1-4alkanediyl-;
with X2a being \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014O\u2014, \u2014C(\u2550O)\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014; and
with X2b being \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014C(\u2550O)\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014;

R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl)amino or R7;
R5 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl or C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl substituted with C1-6alkyloxycarbonyl;
R6 is C1-4alkyl, amino, mono- or di(C1-4alkyl)amino or polyhaloC1-4alkyl;
R7 is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono or di(C1-6alkyl)aminoC1-6alkyl, formyl, C1-6alkylcarbonyl,
C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, C1-6alkylthio, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, \u2014CH(\u2550N\u2014O\u2014R8), R7a, \u2014X3\u2014R7a or R7a\u2014C1-4alkyl;

R7a is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono or di(C1-6alkyl)aminoC1-6alkyl, formyl, C1-6alkylcarbonyl,
C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, C1-6alkylthio, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, \u2014CH(\u2550N\u2014O\u2014R8);

n is 0, 1, 2, 3 or 4; and in case -a=a2-a3=a4- is (a-1), then n may also be 5;
m is 1, 2, 3 and in case -b1=b2-b3=b4- is (b-1), then m may also be 4;
R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; C1-6alkyloxyC1-6alkylcarbonyl substituted with C1-6alkyloxycarbonyl;
each R2 independently is hydroxy, halo, C1-6alkyl optionally substituted with cyano or \u2014C(\u2550O)R6, C3-7cycloalkyl, C2-6alkenyl optionally substituted with one or more halogen atoms or cyano, C2-6alkynyl optionally substituted with one or more halogen atoms or cyano, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethylthio, \u2014S(\u2550O)pR6, \u2014NH\u2014S(\u2550O)pR6, \u2014C(\u2550O)R6, \u2014NHC(\u2550O)H, \u2014C(\u2550O)NHNH2, \u2014NHC(\u2550O)R6, \u2014C(\u2550NH)R6 or a radical of formula
wherein each A1 independently is N, CH or CR6; and
A2 is NH, O, S or NR6;
X1 is \u2014NR5\u2014, \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014O\u2014, \u2014C(\u2550O)\u2014, C1-4alkanediyl, \u2014CHOH\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014, \u2014X2\u2014C1-4alkanediyl- or \u2014C1-4alkanediyl-X2\u2014;
X2 is \u2014NR5\u2014, \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014O\u2014, \u2014C(\u2550O)\u2014, \u2014CHOH\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014;
R3 is NHR13; NR13R14; \u2014C(\u2550O)\u2014NHR13; \u2014C(\u2550O)\u2014NR13R14; \u2014C(\u2550O)\u2014R15; \u2014CH\u2550N\u2014NH\u2014C(\u2550O)\u2014R16; C1-6alkyl substituted with one or more substituents each independently selected from cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; C1-6alkyl substituted with one or more substituents each independently selected from cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7 and wherein 2 hydrogen atoms bound at the same carbon atom are replaced by C1-4alkanediyl; C1-6alkyl substituted with hydroxy and a second substituent selected from cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; C1-6alkyloxyC1-6alkyl optionally substituted with one or more substituents each independently selected from cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; C2-6alkenyl substituted with one or more substituents each independently selected from halo, cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; C2-6alkynyl substituted with one or more substituents each independently selected from halo, cyano, NR9R10, \u2014C(\u2550O)\u2014NR9R10, \u2014C(\u2550O)\u2014C1-6alkyl or R7; \u2014C(\u2550N\u2014O\u2014R8)\u2014C1-4alkyl; R7 or \u2014X3\u2014R7;
X3 is \u2014NR5\u2014, \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014O\u2014, \u2014C(\u2550O)\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014, \u2014X2\u2014C1-4alkanediyl-, \u2014C1-4alkanediyl-X2a\u2014, \u2014C1-4alkanediyl-X2b\u2014C1-4alkanediyl, \u2014C(\u2550N\u2014OR8)\u2014C1-4alkanediyl-;
with X2a being \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014O\u2014, \u2014C(\u2550O)\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014; and
with X2b being \u2014NH\u2014NH\u2014, \u2014N\u2550N\u2014, \u2014C(\u2550O)\u2014, \u2014S\u2014, \u2014S(\u2550O)p\u2014;

R8 is hydrogen, C1-4alkyl, aryl or arylC1-4alkyl;
R9 and R10 each independently are hydrogen; hydroxy; C1-6alkyl; C1-6alkyloxy; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; amino; mono- or di(C1-6alkyl)amino; mono- or di(C1-6alkyl)aminocarbonyl; \u2014CH(\u2550NR11) or R7, wherein each of the aforementioned C1-6alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C1-6alkyloxy, hydroxyC1-6alkyloxy, carboxyl, C1-6alkyloxycarbonyl, cyano, amino, imino, mono- or di(C1-4alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, \u2014S(\u2550O)pR6, \u2014NH\u2014S(\u2550O)pR6, \u2014C(\u2550O)R6, \u2014NHC(\u2550O)H, \u2014C(\u2550O)NHNH2, \u2014NHC(\u2550O)R6, \u2014C(\u2550NH)R6, R7; or
R9 and R10 may be taken together to form a bivalent radical of formula
\u2014CH2\u2014CH2\u2014CH2\u2014CH2\u2014\u2003\u2003(d-1)
\u2014CH2\u2014CH2\u2014CH2\u2014CH2\u2014CH2\u2014\u2003\u2003(d-2)
\u2014CH2\u2014CH2\u2014O\u2014CH2\u2014CH2\u2014\u2003\u2003(d-3)
\u2014CH2\u2014CH2\u2014S\u2014CH2\u2014CH2\u2014\u2003\u2003(d-4)
\u2014CH2\u2014CH2\u2014NR12\u2014CH2\u2014CH2\u2014\u2003\u2003(d-5)
\u2014CH2\u2014CH\u2550CH\u2014CH2\u2014\u2003\u2003(d-6)
R11 is cyano; C1-4alkyl optionally substituted with C1-4alkyloxy, cyano, amino, mono- or di(C1-4alkyl)amino or aminocarbonyl; C1-4alkylcarbonyl; C1-4alkyloxycarbonyl; aminocarbonyl; mono- or di(C1-4alkyl)aminocarbonyl;
R12 is hydrogen or C1-4alkyl;
R13 and R14 each independently are C1-6alkyl optionally substituted with cyano or aminocarbonyl, C2-6alkenyl optionally substituted with cyano or aminocarbonyl, C2-6alkynyl optionally substituted with cyano or aminocarbonyl;
R15 is C1-6alkyl substituted with cyano or aminocarbonyl;
R16 is C1-6alkyl optionally substituted with cyano or aminocarbonyl, or R7;
p is 1 or 2;
aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono or di(C1-6alkyl)aminoC1-6alkyl, C1-6alkylcarbonyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, C1-6alkylthio, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, R7 or \u2014X3\u2014R7; and (b) another antiretroviral compound.
3. A combination containing (a) a compound of formula (I\u2032\u2033)
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein
R1, R2, R3, R4, m and X1 are as defined in claim 1;
n\u2032 is 0, 1, 2, 3 or 4;
R2\u2032 is halo, C1-6alkyl, trihalomethyl, cyano, aminocarbonyl, C1-6alkyl substituted with cyano or aminocarbonyl; and (b) another antiretroviral compound.
4. The combination as claimed in claim 3 wherein R2\u2032 is cyano, aminocarbonyl or C1-6alkyl substituted with cyano or aminocarbonyl.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound of formula (I\u2032\u2033)
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein
R1, R2, R3, R4, m and X1 are as defined in claim 2;
n\u2032 is 0, 1, 2, 3 or 4;
R2\u2032 is halo, C1-6alkyl, trihalomethyl, cyano, aminocarbonyl, C1-6alkyl substituted with cyano or aminocarbonyl; and (b) another antiretroviral compound.
6. The composition as claimed in claim 5 wherein R2\u2032 is cyano, aminocarbonyl or C1-6alkyl substituted with cyano or aminocarbonyl.
7. A combination as claimed in claim 1 wherein the compound of formula (I) is 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitrile having the following structure
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof.
8. A combination as claimed in claim 7 wherein the compound of formula (I) is 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitrile having the following structure
9. A combination as claimed in claim 7 wherein the compound of formula (I) is a compound having the following structure
or a pharmaceutically acceptable addition salt thereof.
10. A combination as claimed in claim 7 wherein the compound of formula (I) is a compound having the following structure
or a pharmaceutically acceptable addition salt thereof.
11. A combination as claimed in claim 9 containing a pharmaceutically acceptable addition salt of 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitrile (E).
12. A combination as claimed in claim 11 wherein the pharmaceutically acceptable addition salt is the hydrochloride salt.
13. A composition as claimed in claim 2 wherein the compound of formula (I) is 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitrile having the following structure
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof.
14. A composition as claimed in claim 13 wherein the compound of formula (I) is 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitrile having the following structure
15. A composition as claimed in claim 13 wherein the compound of formula (I) is a compound having the following structure
or a pharmaceutically acceptable addition salt thereof.
16. A composition as claimed in claim 13 wherein the compound of formula (I) is a compound having the following structure
or a pharmaceutically acceptable addition salt thereof.
17. A composition as claimed in claim 15 containing a pharmaceutically acceptable addition salt of 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitrile (E).
18. A composition as claimed in claim 17 wherein the pharmaceutically acceptable addition salt is the hydrochloride salt.
19. A combination or pharmaceutical composition as claimed in claim 9 or 15 wherein the other antiretroviral compound is a nucleoside reverse transcriptase inhibitor.
20. A combination or pharmaceutical composition as claimed in claim 12 or 18 wherein the other antiretroviral compound is a nucleoside reverse transcriptase inhibitor.
21. A combination or pharmaceutical composition as claimed in claim 19 or 20 wherein the nucleoside reverse transcriptase inhibitor is selected from zidovudine, didanosine, zalcitabine, lamivudine, stavudine or abacavir.
22. A combination or pharmaceutical composition as claimed in claim 9 or 15 wherein the other antiretroviral compound is a nucleotide-like reverse transcriptase inhibitor.
23. A combination or pharmaceutical composition as claimed in claim 12 or 18 wherein the other antiretroviral compound is a nucleotide-like reverse transcriptase inhibitor.
24. A combination or pharmaceutical composition as claimed in claim 22 or 23 wherein the nucleotide-like reverse transcriptase inhibitor is tenofovir.
25. A combination or pharmaceutical composition as claimed in claim 9 or 15 wherein the other antiretroviral compound is a protease inhibitor.
26. A combination or pharmaceutical composition as claimed in claim 12 or 18 wherein the other antiretroviral compound is a protease inhibitor.
27. A combination or pharmaceutical composition as claimed in claim 25 or 26 wherein the protease inhibitor is selected from indinavir, ritonavir, saquinavir, lopinavir, nelfinavir, amprenavir, BMS-232632 or VX-175.
28. A compound of formula
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein

-a1=a2-a3=a4- represents a bivalent radical of formula
\u2014CH\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(a-1);
\u2014N\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(a-2);
\u2014N\u2550CH\u2014N\u2550CH\u2014\u2003\u2003(a-3);
\u2014N\u2550CH\u2014CH\u2550N\u2014\u2003\u2003(a-4);
\u2014N\u2550N\u2014CH\u2550CH\u2014\u2003\u2003(a-5);
-b1=b2-b3=b4- represents a bivalent radical of formula
\u2014CH\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(b-1);
\u2014N\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(b-2);
\u2014N\u2550CH\u2014N\u2550CH\u2014\u2003\u2003(b-3);
\u2014N\u2550CH\u2014CH\u2550N\u2014\u2003\u2003(b-4);
\u2014N\u2550N\u2014CH\u2550CH\u2014\u2003\u2003(b-5);

-a=a2-a3=a4- represents a bivalent radical of formula
\u2014CH\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(a-1);
\u2014N\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(a-2);
\u2014N\u2550CH\u2014N\u2550CH\u2014\u2003\u2003(a-3);
\u2014N\u2550CH\u2014CH\u2550N\u2014\u2003\u2003(a-4);
\u2014N\u2550N\u2014CH\u2550CH\u2014\u2003\u2003(a-5);
-b1=b2-b3=b4- represents a bivalent radical of formula
\u2014CH\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(b-1);
\u2014N\u2550CH\u2014CH\u2550CH\u2014\u2003\u2003(b-2);
\u2014N\u2550CH\u2014N\u2550CH\u2014\u2003\u2003(b-3);
\u2014N\u2550CH\u2014CH\u2550N\u2014\u2003\u2003(b-4);
\u2014N\u2550N\u2014CH\u2550CH\u2014\u2003\u2003(b-5);

R8 is hydrogen, C1-4alkyl, aryl or arylC1-4alkyl;
p is 1 or 2;
aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono or di(C1-6alkyl)aminoC1-6alkyl, C1-6alkylcarbonyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, C1-6alkylthio, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, R7 or \u2014X3\u2014R7;
and C2-6alkenyl\u2032 represents C2-6alkenyl optionally substituted with cyano.
32. A compound of formula
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein R4 is C1-6alkyl and X1 is \u2014NH\u2014 or \u2014O\u2014.
33. A compound as claimed in claim 32 wherein X1 is NH.
34. A compound as claimed in claim 33 wherein R4 is methyl.
35. A compound as claimed in claim 32 having the following formula
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof.
36. A compound as claimed in claim 35 wherein the compound is
37. A compound as claimed in claim 35 wherein the compound is a stereochemically isomeric form of
or a pharmaceutically acceptable addition salt thereof.
38. A compound as claimed in claim 35 wherein the compound is a stereochemically isomeric form of
39. A compound as claimed in claim 35 wherein the compound is
40. A compound as claimed in claim 35 wherein the compound is a pharmaceutically acceptable addition salt of
41. A compound as claimed in claim 40 wherein the compound is

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of remanufacturing a replaceable consumable unit comprising:
providing the replaceable consumable unit comprising a first electronic circuit, said first electronic circuit at least partially inoperable;
providing a second electronic circuit;
communicatively connecting the second electronic circuit to the first electronic circuit; and
intercepting, by the second electronic circuit, signals sent by an imaging system to the first electronic circuit.
2. The method of claim 1 further comprising:
transmitting, by the second electronic circuit, a portion of the intercepted signals to the first electronic circuit.
3. The method of claim 2 wherein the intercepted signals transmitted to the first electronic circuit comprise at least a portion of an authentication sequence.
4. The method of claim 3 further comprising:
processing, by the second electronic circuit, intercepted signals not transmitted to the first electronic circuit.
5. The method of claim 4 wherein the intercepted signals processed by the second electronic circuit comprise commands to write memory storing a value corresponding to the amount of toner remaining in the replaceable consumable unit.
6. The method of claim 4 wherein the intercepted signals processed by the second electronic circuit comprise commands to read memory storing a value corresponding to the amount of toner remaining in the replaceable consumable unit.
7. The method of claim 1 wherein the first electronic circuit comprises a memory address which cannot be overwritten.
8. The method of claim 7 wherein the value stored at the memory address indicates that no useable toner remains in the replaceable consumable unit.
9. The method of claim 8 wherein the intercepted signals comprise a command to read the memory address.
10. The method of claim 8 wherein the intercepted signals comprise a command to write the memory address.
11. The method of claim 2 further comprising:
intercepting, by the second electronic circuit, signals sent by the first electronic circuit to the imaging system.
12. The method of claim 11 further comprising:
transmitting, by the second electronic circuit, to the imaging system at least a portion of the signals intercepted from the first electronic circuit.
13. The method of claim 12 wherein the signals transmitted to the imaging system comprise at least a portion of an authentication sequence.
14. A remanufactured replaceable consumable unit comprising:
a first electronic circuit, said first electronic circuit at least partially inoperable; and
a second electronic circuit communicatively connected to the first electronic circuit, said second electronic circuit intercepting signals sent by an imaging system to the first electronic circuit.
15. The remanufactured replaceable consumable unit of claim 14 wherein the second electronic circuit transmits a portion of the intercepted signals to the first electronic circuit.
16. The remanufactured replaceable consumable unit of claim 15 wherein the intercepted signals transmitted to the first electronic circuit comprise at least a portion of an authentication sequence.
17. The remanufactured replaceable consumable unit of claim 16 wherein the second electronic circuit processes intercepted signals not transmitted to the first electronic circuit.
18. The remanufactured replaceable consumable unit of claim 17 wherein the intercepted signals processed by the second electronic circuit comprise commands to write memory storing a value corresponding to the amount of toner remaining in the replaceable consumable unit.
19. The remanufactured replaceable consumable unit of claim 17 wherein the intercepted signals processed by the second electronic circuit comprise commands to read memory storing a value corresponding to the amount of toner remaining in the replaceable consumable unit.
20. The remanufactured replaceable consumable unit of claim 14 wherein the first electronic circuit comprises a memory address which cannot be overwritten.